Login to Your Account



Financings Roundup

XOMA Raising $39.2M Publicly for Phase II Gevokizumab Trial

By Staff Reports


Wednesday, March 7, 2012

Less than two months after disclosing plans to trim its staff and kickstarting its commercial operations by in-licensing an approved hypertension drug, XOMA Corp. priced a public offering to raise about $39.2 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription